Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $4.37, for a total value of $961,400.00. Following the completion of the transaction, the director owned 6,869,863 shares in the company, valued at approximately $30,021,301.31. This represents a 3.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Recursion Pharmaceuticals Stock Down 2.5%

RXRX stock opened at $4.80 on Friday. The firm has a 50-day moving average price of $5.13 and a 200-day moving average price of $5.12. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2.50 billion, a P/E ratio of -2.66 and a beta of 0.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. During the same period in the prior year, the company earned ($0.34) EPS. The firm’s quarterly revenue was down 80.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. increased its position in Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. AlphaQuest LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Recursion Pharmaceuticals by 97.2% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after purchasing an additional 4,446 shares during the last quarter. Allworth Financial LP increased its position in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares during the period. Finally, Janney Montgomery Scott LLC bought a new position in Recursion Pharmaceuticals during the second quarter worth $51,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.